Methods of treatment using a jak inhibitor compound
AssigneeTheravance Biopharma R&D IP, LLC
InventorsMELANIE A. KLEINSCHEK, GLENN D. CRATER
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.
Claims22
1-4. (canceled)
A method of treating sarcoidosis in a human, the method comprising administering to the human a pharmaceutical composition comprising 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.
9-14. (canceled)
A method of treating sarcoidosis in a mammal, the method comprising administering to the mammal the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.